Table 1.

Limitations of hard end point studies

Low incidence of events
Big numbers and long follow-up
Lack of information of preclinical lesions
Uncertainty on the protection mechanism of treatment
Difficulties in establishing the correct cost-benefit ratio of treatment
High cost (mostly affordable by possibly biased sponsors)